The biochemical effects seen in MHH-CALL4 cells (Fig. 6D) following single-agent and combination treatment with JQ1 and ruxolitinib were also observed in Eμ-Crlf2/Jak2R683G B-ALL cells following in vivo treatment with these agents (Fig. 6I), highlighted by the almost complete loss of c-Myc following combination treatment. Here, MYC is linked to acute lymphoblastic leukemia.